Solcitinib
A potent, selective JAK1 inhibitor for the treatment of psoriasis, lupus, and ulcerative colitis.Psoriasis Phase 2 Clinical (In Vitro) :Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
Product Specifications
CAS Number
1206163-45-2
Product Name Alternative
GSK-2586184 | GLPG-0778
Purity
>98% (HPLC)
Solubility
DMSO: 20 mg/mL
Smiles
CC1 (CN (C1) C (=O) C2=CC=C (C=C2) C3=CC=CC4=NC (=NN43) NC (=O) C5CC5) C
Molecular Formula
C22H23N5O2
Molecular Weight
389.4503
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Cyclopropanecarboxamide, N-[5-[4-[ (3,3-dimethyl-1-azetidinyl) carbonyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Alteromonas macleodii Deoxycytidine triphosphate deaminase (dcd)
Recombinant Alteromonas macleodii Deoxycytidine triphosphate deaminase (dcd)
Recombinant Alteromonas macleodii Deoxycytidine triphosphate deaminase (dcd)
Recombinant Alteromonas macleodii Deoxycytidine triphosphate deaminase (dcd)
Recombinant Alteromonas macleodii Deoxycytidine triphosphate deaminase (dcd)